Standalone and Consolidated Un-Audited Financial Results of the Company for the quarter ended
As filed · Outcome of Board Meeting
What happened
FactStandalone and Consolidated Un-Audited Financial Results of the Company for the quarter ended. The aforesaid Standalone and Consolidated Unaudited Financial Results, as approved by the Board. The said financial results shall also be made available on the Company’s website at Quarterly.
Why it matters
CapitSignal interpretationReported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Demand
DelayedIn the second quarter we are expecting a major push from Arrotex on that Macrogol new molecule which we launched.
And in third and fourth quarter we see a lot of progress coming from Ibuprofen and Clarithromycin granules.
Change
FactImplication
CapitSignal interpretationGuidance
RevisedLooking ahead, on the domestic side we are focused on expanding our ethical footprint into peninsular India and into high-growth chronic therapeutic categories, targeting 15-20% CAGR growth in this business.
We expect FY27 to witness revenue growth of more than 50%.
Change
FactImplication
CapitSignal interpretationGuidance
WithdrawnFY30 is very long way to go, but yes, we would look for a revenue of minimum ₹1500 crores of a revenue and maybe a net profit of approx ₹200 plus.
We may revise this. We don't want to overproject and want to say that we'll do this one year in advance. But by the end of the financial year, we'll revisit all these numbers.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Margin trend against the prior period
- Cash from operations against reported profit
- Whether prior guidance is reaffirmed
- We expect FY27 to witness revenue growth of more than 50%. (management committed by FY27)
- A key milestone was the commercialization of the Viatris (USA), Manx (UK) and Arrotex (Australia) CDMO partner (management committed by FY27)
Evidence
- Ind-Swift Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.(opens the original filing in a new tab)
- Earlier statement · Q1 FY27
- Latest statement · Q1 FY27
- Earlier statement · Q1 FY27
- Latest statement · Q1 FY27
- Earlier statement · Q1 FY27
- Latest statement · Q1 FY27
How CapitSignal classified this
- Reasoning:
- RESULTS base 68; +6 corroborating keywords; +5 quantified amount; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%